TNF and acute graft versus host disease: Interleukin-1 and TNF-α also play a central role in the development of acute GVHD, but drugs that target these cytokine/chemokine-receptor interactions (etanercept, infliximab) failed to improve incidence rates of acute GVHD [68, 69].